Effects doxazosin blood pressure renin-angiotensin-aldosterone urinary kallikrein Doxazosin new quinazoline-derivative postsynaptic alpha antagonist randomized double-blind placebo-controlled study effects blood pressure BP heart rate metabolic functions renal hormones administration single oral morning dose fashion patients women men years mild uncomplicated essential hypertension antihypertensive effective dose biweekly mg/day mean end titration-point dose mg mean standard error mean week treatment diastolic BP levels equal mm Hg weeks treatment final mean dose mg/day BP patients mean supine mm Hg increase heart rate first-dose phenomenon renin-aldosterone system electrolyte excretion Renal function metabolic parameters unchanged Urinary kallikrein excretion good tolerance patient study dry nose results long-term monotherapy doxazosin effective safe antihypertensive agent mild essential hypertension urinary kallikrein excretion 